全文获取类型
收费全文 | 2439篇 |
免费 | 105篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 52篇 |
妇产科学 | 21篇 |
基础医学 | 312篇 |
口腔科学 | 60篇 |
临床医学 | 149篇 |
内科学 | 681篇 |
皮肤病学 | 67篇 |
神经病学 | 270篇 |
特种医学 | 98篇 |
外科学 | 288篇 |
综合类 | 3篇 |
预防医学 | 51篇 |
眼科学 | 36篇 |
药学 | 195篇 |
中国医学 | 7篇 |
肿瘤学 | 248篇 |
出版年
2023年 | 11篇 |
2022年 | 36篇 |
2021年 | 62篇 |
2020年 | 20篇 |
2019年 | 40篇 |
2018年 | 49篇 |
2017年 | 37篇 |
2016年 | 50篇 |
2015年 | 39篇 |
2014年 | 42篇 |
2013年 | 69篇 |
2012年 | 123篇 |
2011年 | 136篇 |
2010年 | 83篇 |
2009年 | 66篇 |
2008年 | 120篇 |
2007年 | 124篇 |
2006年 | 100篇 |
2005年 | 110篇 |
2004年 | 115篇 |
2003年 | 115篇 |
2002年 | 104篇 |
2001年 | 91篇 |
2000年 | 93篇 |
1999年 | 78篇 |
1998年 | 22篇 |
1997年 | 23篇 |
1996年 | 29篇 |
1995年 | 23篇 |
1994年 | 15篇 |
1993年 | 17篇 |
1992年 | 58篇 |
1991年 | 46篇 |
1990年 | 40篇 |
1989年 | 35篇 |
1988年 | 26篇 |
1987年 | 42篇 |
1986年 | 28篇 |
1985年 | 38篇 |
1984年 | 30篇 |
1983年 | 23篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 13篇 |
1979年 | 17篇 |
1978年 | 10篇 |
1977年 | 8篇 |
1972年 | 11篇 |
1970年 | 8篇 |
1969年 | 8篇 |
排序方式: 共有2551条查询结果,搜索用时 15 毫秒
71.
Kazuya Abe Yuichi Ishikawa Michio Fujiwara Hiroko Yukawa Takeshi Yanagihara Saori Takei Hitoshi Arioka Yasuhiko Kita 《Medicine》2022,101(2)
Rationale:Immune checkpoint inhibitors (ICIs) have shown efficacy for the treatment of various kinds of malignant tumors. However, ICIs can cause immune-related adverse events, such as arthritis. Nevertheless, the treatment of ICI-induced arthritis has not been established yet. Here we report a case of ICI-induced polyarthritis successfully treated using sarilumab and monitored using joint ultrasonography.Patient concerns:A 61-year-old man presented with polyarthritis. He had been treated with nivolumab for recurrent renal cell carcinoma 11 months before. He developed ICI-induced nephritis (proteinuria and elevated serum creatinine) 3 months before, which resolved after discontinuing nivolumab for 1 month. Two months after resuming nivolumab, he developed polyarthralgia and joint swelling, which were suspected to be associated with nivolumab administration, and hence we discontinued nivolumab again. Laboratory tests revealed elevated C-reactive protein level and erythrocyte sedimentation rate, but were negative for rheumatoid factor and anti-cyclic citrullinated peptide antibody. Joint ultrasonography revealed active synovitis in several joints, but a joint X-ray revealed no bone erosion.Diagnoses:We diagnosed polyarthritis as ICI-induced arthritis because the findings were not typical of rheumatoid arthritis (no bone erosion and seronegativity) and the patient had already developed other immune-related adverse events (ICI-induced nephritis).Interventions:After discontinuation of nivolumab, we started treatment with 15 mg daily prednisolone and 1000 mg daily sulfasalazine, although it was ineffective. Hence, we initiated 200 mg biweekly sarilumab.Outcomes:Following sarilumab administration, polyarthritis improved rapidly, and joint ultrasonography confirmed the rapid improvement of synovitis. Hence, we tapered off the glucocorticoid treatment. No recurrence of renal cell carcinoma was noted for 2 years after the initiation of sarilumab despite no anti-tumor therapy.Lessons:Sarilumab may serve as a good treatment option for treating refractory ICI-induced polyarthritis. Joint ultrasonography may contribute to the evaluation of ICI-induced polyarthritis and monitoring the effects of treatments. 相似文献
72.
Mamiko Onuki Koji Matsumoto Takashi Iwata Kasumi Yamamoto Yoichi Aoki Shoji Maenohara Naotake Tsuda Shoji Kamiura Kazuhiro Takehara Koji Horie Nobutaka Tasaka Hideaki Yahata Yuji Takei Yoichi Aoki Hisamori Kato Takeshi Motohara Keiichiro Nakamura Mitsuya Ishikawa Tatsuya Kato Hiroyuki Yoshida Noriomi Matsumura Hidekatsu Nakai Shogo Shigeta Fumiaki Takahashi Kiichiro Noda Nobuo Yaegashi Hiroyuki Yoshikawa 《Cancer science》2020,111(7):2546-2557
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women. 相似文献
73.
Kenji Yasue Hiraku Fuse Satoshi Oyama Koichi Hanada Kazuya Shinoda Hideaki Ikoma Tatsuya Fujisaki Yoshio Tamaki 《Journal of radiation research》2022,63(1):137
This study aimed to quantitatively clarify the baseline drift for each respiratory cycle in two respiratory-gating methods using the intra-beam respiratory motion data of lung cancer patients. The residual motion and dose distribution were calculated based on intra-beam respiratory motion data with the baseline drift. To quantify the baseline drift during irradiation, it was defined as the inclination between the detected expiration point and the expiration point in the next cycle in the anterior–posterior (AP), cranial–caudal (CC) and left–right (LR) directions obtained using an in-house programme. The baseline drift value reached up to 0.74 mm/s in the CC direction as per the respiratory motion data of 10 patients. The homogeneity index (HI) of the phase-gating method tended to increase because the target was irradiated even when the amplitude position of the target differed from period to period. In contrast, the amplitude-gating method enabled irradiation considering the amplitude position of the target because the gating window was set considering the amplitude position of the respiratory motion. The respiratory-gating methods and respiratory phase in respiratory-gating lung stereotactic body radiation therapy (SBRT) must be determined based on the respiratory motion of the patients. 相似文献
74.
Taito Mahoko Taito Shunsuke Banno Masahiro Fujiwara Takashi Okamura Hitoshi Tsujimoto Hiraku Kataoka Yuki Tsujimoto Yasushi 《European archives of oto-rhino-laryngology》2019,276(6):1573-1583
European Archives of Oto-Rhino-Laryngology - We aimed to determine whether voice rehabilitation after radiotherapy improves the quality of life (QOL), voice function, and self-rated voice function... 相似文献
75.
Katsuaki Suzuki Kenji Hashimoto Yasuhide Iwata Kazuhiko Nakamura Masatsugu Tsujii Kenji J Tsuchiya Yoshimoto Sekine Shiro Suda Genichi Sugihara Hideo Matsuzaki Toshiro Sugiyama Masayoshi Kawai Yoshio Minabe Nori Takei Norio Mori 《Neuropsychopharmacology》2007,62(3):267-269
BACKGROUND: The neurobiological basis for autism remains poorly understood. Given the role of growth factors in brain development, we hypothesized that epidermal growth factor (EGF) may play a role in the pathophysiology of autism. In this study, we examined whether serum levels of EGF are altered in adult subjects with high-functioning autism. METHODS: We measured serum levels of EGF in the 17 male subjects with high-functioning autism and 18 age-matched healthy male subjects. RESULTS: The serum levels of EGF in the subjects with high-functioning autism (72.4 +/- 102.8 pg/mL [mean +/- SD]) were significantly lower (Mann-Whitney U = 22.0, p < .001) than those of normal control subjects (322.3 +/- 122.0 pg/mL [mean +/- SD]). However, there were no correlations between serum EGF levels and clinical variables in the subjects with autism. CONCLUSIONS: This study suggests that decreased levels of EGF might be implicated in the pathophysiology of high-functioning autism. 相似文献
76.
Kazuo Yamada Kazuhiko Nakamura Yoshio Minabe Yoshimi Iwayama-Shigeno Hitomi Takao Tomoko Toyota Eiji Hattori Noriyoshi Takei Yoshimoto Sekine Katsuaki Suzuki Yasuhide Iwata Ko Miyoshi Akiko Honda Kousuke Baba Taiichi Katayama Masaya Tohyama Norio Mori Takeo Yoshikawa 《Neuropsychopharmacology》2004,56(9):683-690
BACKGROUND: DISC1 has been suggested as a causative gene for psychoses in a large Scottish family. We recently identified FEZ1 as an interacting partner for DISC1. To investigate the role of FEZ1 in schizophrenia and bipolar disorder, case-control association analyses were conducted in Japanese cohorts. METHODS: We performed a mutation screen of the FEZ1 gene and detected 15 polymorphisms. Additional data on informative polymorphisms were obtained from public databases. Eight single nucleotide polymorphisms (SNPs) were analyzed in 119 bipolar disorder and 360 schizophrenic patients and age- and gender-matched control subjects. All genotypes were determined with the TaqMan assay, and selected samples were confirmed by sequencing. RESULTS: The two adjacent polymorphisms displayed a nominally significant association with schizophrenia (IVS2+ 1587G>A, p = .014; 396T相似文献
77.
Katsuya Yanagisawa Kenichi Nishie Hidekazu Takahashi Kenji Sano Kazuyoshi Takei Hiroshi Yamamoto Tomonobu Koizumi Masayuki Hanaoka 《Internal medicine (Tokyo, Japan)》2022,61(6):883
A 71-year-old man presented with cough and bloody sputum. Computed tomography showed a mass in the lower lobe of the left lung. Histological findings in biopsy tissue revealed a malignant peripheral nerve sheath tumor (MPNST). The patient was diagnosed with primary lung MPNST based on a systemic examination. Although initial chemotherapy treatment with doxorubicin failed to control the disease, radiotherapy considerably shrank the tumor. Primary lung MPNSTs are rare, and there is no established treatment for inoperable cases. This case suggests that radiotherapy is a treatment option for primary lung MPNST. 相似文献
78.
Nobuyuki Enomoto † Kenichi Ikejima † Blair U Bradford Chantal A Rivera Hiroshi Kono Moritaka Goto Shunhei Yamashina Peter Schemmer Tsuneo Kitamura † Hirosumi Oide † Yoshiyuki Takei † Miyoko Hirose † Hidetake Shimizu † Akihisa Miyazaki † David A Brenner ‡ Nobuhiro Sato† and Ronald G Thurman 《Journal of gastroenterology and hepatology》2000,15(S1):20-25
79.
80.
Miyazawa K Ohyashiki K Urabe A Hata T Nakao S Ozawa K Ishikawa T Kato J Tatsumi Y Mori H Kondo M Taniguchi J Tanii H Rojkjaer L Omine M 《International journal of hematology》2008,88(1):73-81
The pharmacokinetics (PK) and pharmacodynamics (PD) of the once-daily, oral ironchelating agent, deferasirox (Exjade((R)), ICL670), have been evaluated further in a Phase I, openlabel, multicenter, dose-escalation study in Japanese patients with myelodysplastic syndromes, aplastic anemia, and other anemias. Deferasirox was initially administered as a single dose of 5 (n = 6), 10 (n = 7), 20 (n = 6) or 30 (n = 7) mg/(kg day) and then after 7 days seven daily doses were administered. Linear PK (C (max) and AUC) were observed at all doses after a single dose and at steady state, and dose-dependent iron excretion was observed. Pharmacokinetic/pharmacodynamic parameters were similar to those reported in a Caucasian beta-thalassemia cohort. Following the single- and multiple-dose phases, 21 of 26 patients progressed to a 3-year extension phase of the study, where dose reductions and increases [5-30 mg/(kg day)] were allowed following safety and efficacy assessments. In the interim, 1-year data show that deferasirox was well tolerated, with generally infrequent and mild adverse events. Reductions in serum ferritin levels were observed and a negative iron balance achieved at doses of 20-30 mg/(kg day). These data suggest that deferasirox has a stable and predictable PK/PD profile, irrespective of underlying disease or race, and a predictable and manageable safety profile suitable for chronic administration. 相似文献